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Methods: The data was obtained through the University of
Michigan Blood and Marrow Transplant Program database,
under an IRB-approved protocol. Demographics, risk factors,
and outcomes were evaluated for all patients with DLBCL
who received an allogeneic transplant between 1996 and
2013.
Results: A total of 112 patients were transplanted between
1996 and 2013. Of these, 33% (n¼37) transformed from
follicular type, 30% (n¼31) had an extranodal component,
and 36% (n¼40) had bone marrow involvement. Twenty-
three (20.5%) patients had a prior autologous transplant.
Overall survival was 46% (95% CI of 36-54%) at 1 year and 26%
(95% CI 17-34%) at ﬁve years; the cumulative incidence of
NRM at one year was 33% (95% CI 25-47%). A high Karnofsky
performance status (KPS) (80%) was the strongest factor
associated with a lower non-relapse mortality (NRM)
(HR¼0.47, p¼0.03). Age, stage of the disease, B-symptoms,
CD34 dose, stem cell source, human leukocyte antigen (HLA)
matching, and conditioning regimen were not signiﬁcantly
associated with NRM. The cumulative incidence of relapse
was 44% (95% CI 35-55%) at one year and 53% (95%CI 42-66%)
at ﬁve years. The cumulative incidence of relapse in patients
without chronic graft-versus-host disease (cGVHD) was
substantially higher than in patients with cGVHD (80% vs.
41%, HR¼2.2, p¼0.1). Relapse accounted for 47% (n¼41) of
the deaths, and the rest (n¼46, 53%) were due to non-relapse
causes. Of these, 39% (n¼18) were due to GVHD-related
causes.
Conclusions: Allogeneic HSCT is a treatment option
for advanced, high risk DLBCL, particularly for patients
with a good performance status, where overall survival
is signiﬁcantly better. Although all-cause mortality and
disease recurrence continue to be high, 26% of thepatients are long-term survivors. In this cohort, cGVHD
was associated with a lower relapse rate, underscoring the
beneﬁts and importance of the graft-versus-lymphoma
effect.270
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Although novel agents improved the outcome of patients
with multiple myeloma (MM), only bortezomib (Bor) is
available for newly diagnosed patients in Japan. We have
started induction therapy with bortezomib-cyclophospha-
mide-dexamethasone (BCD) for newly diagnosed MM
(NDMM) patients since Nov. 2011. Here we report the ef-
ﬁcacy and the feasibility of this induction therapy for
transplant eligible NDMM. Twenty-nine patients received
BCD as induction therapy between Nov. 2011 and Nov.
2013 in our institute. BCD is composed of CPA 300mg/m2
po, Bor 1.3mg/m2 iv or sc, and Dex 40mg/body po on day 1,
8, 15, and 22 with 28 days cycle. Median age was 55 (range
31-67), M/F 18/11, IgG/IgA/IgE/BJ 13/7/1/8, and ISS I/II/III
14/10/5. Eight out of 29 had t(11;14) and 2 had t(4;14).
Median cycles of BCD were 4 (range 2-6), except for one
patient who progressed during ﬁrst cycle. Grade 4 neu-
tropenia (<500/mL) was observed in 2 patients and no
grade 2 thrombocytopenia (<75K/mL) was observed. Grade
3 non-hematologic adverse event was observed in one
patient with varicella-zoster virus reactivation. Response
after BCD was sCR 6, CR 0, VGPR 9, PR 6, MR 3, SD 3, PD 2
(PR 72%, VGPR 52%, and sCR 21%). Two years progres-
sion free survival (PFS) was 78.3% (95% CI: 54.7-90.6).
Autologous stem cell harvest was performed in 27 patients.
Seventeen of 27 patients received high dose melphalan
and ASCT immediately (“upfront” group), while the other
10 patients were scheduled for no ASCT until PD (“late”
group). Maximal response was PR 94%, VGPR 76%, CR
65%, and sCR 59% in “upfront” group, and PR 90%, VGPR
60%, CR 50%, and sCR 40% in “late” group. Two and one
patients have been diagnosed as PD in “upfront” group and
“late” group, respectively. Two years PFS in “upfront”
group was 82.1% (95%CI: 44.4-95.3). Although follow up
period is still short, there was no difference in OS and PFS
between two groups. Our data suggest the efﬁcacy and the
feasibility of BCD for transplant eligible NDMM, but longer
follow up is needed.
